BioCentury
ARTICLE | Clinical News

Arcus reports Phase I safety data for cancer candidate AB928

May 11, 2018 5:49 PM UTC

Arcus Biosciences Inc. (NYSE:RCUS) reported data from 85 healthy volunteers in a Phase I trial showing that single and multiple ascending doses of cancer candidate AB928 were well tolerated. Data were presented at the American Association for Cancer Research meeting in Chicago.

The company plans to report final data from the double-blind, placebo-controlled trial in mid-2018. AB928 is an adenosine A2A receptor (ADORA2A) and ADORA2B antagonist...